STOCK TITAN

Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Atea Pharmaceuticals director Arthur S. Kirsch received new equity awards. He was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026 and are fully vested by June 18, 2027, subject to his continued service.

Kirsch also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service through the vesting date.

Positive

  • None.

Negative

  • None.
Insider KIRSCH ARTHUR S
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 26,700 $0.00 --
Grant/Award Stock Option (Right to Buy) 37,700 $0.00 --
Holdings After Transaction: Restricted Stock Units — 26,700 shares (Direct, null); Stock Option (Right to Buy) — 37,700 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
Stock options granted 37,700 options Grant to Arthur S. Kirsch on June 18, 2026
Option exercise price $4.36 per share Exercise price of granted stock options
Option expiration June 17, 2036 Expiration date of stock options
RSUs granted 26,700 RSUs Grant to Arthur S. Kirsch on June 18, 2026
Option vesting period end June 18, 2027 Options fully vested by this date if service continues
RSU vesting trigger window Next annual meeting after June 18, 2026 or June 18, 2027 Single-installment RSU vesting condition
Restricted Stock Units financial
"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price": "4.3600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIRSCH ARTHUR S

(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/18/2026A26,700 (2) (2)Common Stock26,700$026,700D
Stock Option (Right to Buy)$4.3606/18/2026A37,700 (3)06/17/2036Common Stock37,700$037,700D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
3. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
/s/ Andrea Corcoran, as Attorney-in-Fact for Arthur S. Kirsch06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Atea Pharmaceuticals (AVIR) director Arthur S. Kirsch receive?

Arthur S. Kirsch received 37,700 stock options and 26,700 restricted stock units. The options have a $4.36 exercise price, while each RSU represents a right to one share of Atea Pharmaceuticals common stock, subject to vesting conditions.

How do Arthur S. Kirsch’s new stock options at Atea Pharmaceuticals (AVIR) vest?

The 37,700 stock options vest in twelve substantially equal monthly installments following June 18, 2026. They become fully vested on June 18, 2027, provided Kirsch continues serving as a director through each applicable vesting date.

When do Arthur S. Kirsch’s restricted stock units in Atea Pharmaceuticals (AVIR) vest?

The 26,700 RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026, or June 18, 2027. Vesting requires Kirsch’s continued service through the applicable vesting date.

What does each restricted stock unit (RSU) represent for Atea Pharmaceuticals (AVIR)?

Each restricted stock unit represents a contingent right to receive one share of Atea Pharmaceuticals common stock. The RSUs only convert into shares if the specified vesting conditions, including continued service through the vesting date, are satisfied.

What is the exercise price and expiration date of Arthur S. Kirsch’s Atea (AVIR) stock options?

The stock options granted to Kirsch carry an exercise price of $4.36 per share and expire on June 17, 2036. He must exercise them before that expiration date, subject to vesting and his continued service conditions.